Document Title

Summary of the residues in or on treated products, food and feed
Spiroxamine EC 500 (500 g/L)

Data Requirement(s)

Regulation (EC) No 1107/2009 & Regulation (EU) No 284/2013

Document MCP

Section 8: Residues in or on treated products, food and feed

According to the Guidance Document SANCO/10181/2013 for applicants on preparing dossiers for the approval of a chemical active substance

Date

2021-03-31

Author(s)

[redacted]

ERM
On behalf of Bayer AG
Crop Science Division

OWNERSHIP STATEMENT

This document, the data contained in it and copyright therein are owned by Bayer AG and/or affiliated entities. No part of the document or any information contained therein may be disclosed to any third party without the prior written authorisation of Bayer AG and/or affiliated entities.

The summaries and evaluations contained in this document are based on unpublished proprietary data submitted for the purpose of the assessment undertaken by the regulatory authority. Other registration authorities should not grant, amend, or renew a registration on the basis of the summaries and evaluation of unpublished proprietary data contained in this document unless they have received the data on which the summaries and evaluation are based, either:

- **from Bayer AG or respective affiliate; or**
- **from other applicants once the period of data protection has expired.**

Version history

Date [yyyy-mm-dd]	Data points containing amendments or additions[1] and brief description	Document identifier and version number

[1] It is suggested that applicants adopt a similar approach to showing revisions and version history as outlined in SANCO/10180/2013 Chapter 4, 'How to revise an Assessment Report'

Table of Contents

CP 8 RESIDUES IN OR ON TREATED PRODUCTS, FOOD OR FEED

Spiroxamine was included in Annex I to Council Directive 91/414/EEC in 1999 (Directive 1999/73/EC, Entry into Force on 1 September 1999). This Supplementary Dossier contains data which were not submitted at the time of the Annex I inclusion and first renewal of spiroxamine under Council Directive 91/414/EEC and which were therefore not evaluated during the first EU review and renewal. However, all studies submitted for the first approval and subsequent first renewal of spiroxamine have also been summarised according to current guidance and included in the dossier. Where studies meet relevant validity criteria, new robust study summaries have been provided in the appropriate dossier section. However, where studies do not meet relevant validity criteria and are not considered acceptable, less detailed summaries may have been provided alongside discussions of study deficiencies. All relied upon study reports are submitted in Document K for this second renewal of approval dossier or in Document K for the previous Annex I inclusion and first renewal submissions.

All data which were already submitted by Bayer AG (former Bayer CropScience) for the Annex I inclusion and first renewal under Council Directive 91/414/EEC are contained in the draft Re-Assessment Report (RAR) 2010 and its revised RAR 2017, and are included in the Baseline Dossier provided by Bayer AG.

Spiroxamine consists of four isomers (two diastereomers each with its corresponding two enantiomers which are in a 1:1 ratio) as shown in the schematic below. The isomer nomenclature presented in some historical documentation may differ with respect to the A/B and corresponding trans/cis notation as a result of a discrepancy in referencing, which is discussed in detail in position paper M-761468-01-1 (see CA 1.7/01). It is recommended that the stereo assignments depicted here, together with the A and B notation should be used exclusively going forward to ensure continuity of information throughout the dossier.



The formulation Spiroxamine EC 500 (500 g/L), abbreviation Spiroxamine EC 500, is an emulsifiable concentrate formulation containing 160 g/L of prothioconazole and 300 g/L of spiroxamine. This formulation is registered throughout Europe under trade names such as BATAM, HOGGAR, IMPULSE EC 500, PROSPER, PROSPER 500 EC. Spiroxamine EC 500 already a representative formulation of Bayer AG for the Annex I inclusion of spiroxamine under Council Directive 91/414/EEC.

All relevant metabolism and residue data in support of this use are summarized in Document MCA, Section 6.